IT Home News on December 16,The male contraceptive, called YCT-529, entered a phase 1 clinical trial in the UK on December 13 and is an important development in the field of contraception.
The male contraceptive pill was created by YourChoice Therapeutics in a phase 1 clinical trial, in which 16 participants were invited to test the pill's safety, tolerability, and oral dose function.
IT House Note: Over the past few decades, women have borne most of the contraceptive burden, from birth control pills to patches to intrauterine devices.
Male contraception mainly includes the use of *** and vasectomy, but it is less acceptable for men because vasectomy is irreversible.
The contraceptive mechanism of YCT-529 is largely dependent on the retinoic acid receptor (RAR-), and the researchers hope to induce durable but reversible birth control by selectively blocking this protein while causing little off-target effects elsewhere (i.e., no interaction with a target outside of the drug's design, i.e., no ***).
RAR- Locally blocks the production of vitamin A (which helps in the production and release of sperm), in existing animal studies, a complete reversal has been observed 14 weeks after discontinuation of use, such a long buffer period also means that missing a pill or two does not pose a high risk of pregnancy.
The drug YCT-529 is 99% effective and 100% reversible in mice